ProVivoX Inc. is specialized in providing a new kind of survival prognosis test, PhiPlex, to cancer patients. While presently available tests often base their prognosis on the detection of a single biomarker, PhiPlex relies on the relative expression of several biomarkers to predict the extent of individual patient survival and, potentially, therapy response. In order to provide a more comprehensive analysis of an individual’s cancer, the expression of multiple protein biomarkers is analyzed using a validated multiplex method coupled with a high-end visualization technique and specific statistical algorithms. The PhiPlex test is a low-cost technology (variable cost: ~200US$/test, target pricing ~1500US$) and is an affordable alternative to presently available prognostic tests (~4000US$). The survival information provided by this low-cost test will allow clinicians to determine the most effective treatment approach and will help patients make the right lifestyle choices.